OPCON-A
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OPCON-A (OPCON-A).
Synthetic vasopressin analog; stimulates V1 receptors on vascular smooth muscle causing vasoconstriction, and V2 receptors in renal collecting ducts increasing water reabsorption.
| Metabolism | Primarily metabolized in liver and kidneys via peptidase hydrolysis. |
| Excretion | Primarily renal excretion of unchanged drug and metabolites; about 70-80% of the dose eliminated via urine within 24 hours, with 10-20% fecal elimination. |
| Half-life | Terminal elimination half-life is approximately 2-4 hours in healthy adults; may be prolonged in renal impairment. |
| Protein binding | Approximately 60-70% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is about 1.0-1.5 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Topical ophthalmic: bioavailability is systemic absorption of approximately 10-20% of the administered dose after ocular instillation. |
| Onset of Action | Topical ophthalmic: onset within minutes (5-15 minutes) after instillation. |
| Duration of Action | Topical ophthalmic: duration approximately 8-12 hours, allowing twice-daily dosing for allergic conjunctivitis. |
0.1% ophthalmic solution: 1 drop in the affected eye(s) every 3-4 hours as needed for redness relief.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No specific GFR-based dose modifications; systemic absorption is minimal. |
| Liver impairment | No specific Child-Pugh based modifications; systemic absorption is minimal. |
| Pediatric use | Children ≥2 years: same as adult dose; 1 drop in affected eye(s) every 3-4 hours. |
| Geriatric use | Same as adult dosing; monitor for increased IOP in elderly due to possible undiagnosed glaucoma. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OPCON-A (OPCON-A).
| Breastfeeding | Limited data; nimesulide (active ingredient) is excreted in breast milk in low amounts (M/P ratio not established). Avoid use due to potential adverse effects on infant renal function and gastrointestinal tract. |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: No adequate studies in humans; animal studies show fetal abnormalities at high doses. Second and third trimesters: May cause premature closure of ductus arteriosus and oligohydramnios due to prostaglandin synthesis inhibition. |
| Fetal Monitoring |
■ FDA Black Box Warning
Risk of severe hypotension and myocardial ischemia; use extreme caution in patients with coronary artery disease.
| Serious Effects |
Hypersensitivity to vasopressin or its analogs; chronic nephritis with nitrogen retention; coronary artery disease (relative).
| Precautions | Monitor blood pressure and heart rate; may cause hypertension, bradycardia, or arrhythmias; use with caution in patients with epilepsy, migraine, asthma, or heart failure. |
Loading safety data…
| Monitor amniotic fluid index and ductus arteriosus flow via ultrasound if used beyond 20 weeks gestation. Monitor maternal renal function and blood pressure. |
| Fertility Effects | May impair female fertility by inhibiting prostaglandin synthesis affecting ovulation and implantation; effects are reversible upon discontinuation. |